C1142946||USP7
C1430988||PTEN
C0023434||chronic lymphocytic leukemia
C0079419||TP53
C0596611||mutated
C0017260||deleted
C0009013||clones
C0023434||Chronic Lymphocytic Leukemia
C0023434||Chronic Lymphocytic Leukemia
C0024314||lymphoproliferative disorder
C1334168||indolent
C1332223||aggressive clinical course
C0392920||treatment regiments
C0184511||improved
C0079419||TP53
C0596611||mutations
C0017260||deletions
C0796349||short arm of chromosome 17
C0796349||del17p
C1142946||USP7
C0294105||de-ubiquitinase
C2244223||cellular homeostasis
C0023434||Chronic Lymphocytic Leukemia
C0023434||Chronic Lymphocytic Leukemia
C0023434||Chronic Lymphocytic Leukemia
C0085983||cell lines
C1142946||USP7
C1514559||over-expressed
C1101610||miR-338-3p
C1101610||miR-181b
C0108555||Casein Kinase 2
C0108555||Casein Kinase 2
C0522505||upstream
C0033684||interactor
C0023434||Chronic Lymphocytic Leukemia
C1142946||USP7
C0014432||inhibitor
C3500983||P5091
C0087111||Treatment
C0023434||Chronic Lymphocytic Leukemia
C0085983||cell lines
C3500983||P5091
C1371476||cell growth arrest
C0162638||apoptosis
C1430988||PTEN
C0079419||TP53
C1883559||wild type
C0014406||null environment
C1430988||PTEN
C0597611||tumor suppressive mediator
C1142946||USP7
C1430988||PTEN
C0080055||p53
C1142946||USP7
C1513403||druggable target
C0023434||Chronic Lymphocytic Leukemia